TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Can't find what you're looking for?
View all search resultsCan't find what you're looking for?
View all search results
The rate of COVID-19 testing in Indonesia has dropped significantly in the last two months as the pandemic situation continues to improve across the country after the Omicron-fueled third wave reached its peak in mid-February.
The pandemic has caused disruption as well as prompted innovation in the pharmaceutical industry, with Roche Diagnostics Indonesia waiting for the government to green-light its at-home COVID-19 test kits for sales and distribution.
With unprecedented numbers of daily cases and deaths in the past week, and a collapsed healthcare system, Indonesia appears to be looking to India -- which managed to reduce the virus spread within two months – in the hope that there could be an end to the current nightmare.
State-owned pharmaceutical holding company PT Bio Farma recently released a spit sample COVID-19 test kit named Bio Saliva developed in cooperation with genomic technology start-up Nusantics.
Despite the ongoing nationwide surge in COVID-19 cases, the positivity rate has remained relatively unchanged, a sign that Indonesia's pandemic response is still hamstrung by low testing capacity and a shortage in medical resources.
The COVID-19 task force will perform more random testing on intercity travelers and tighten checks on people traveling from Sumatra amid the rise of confirmed cases in Indonesia's westernmost island.
